Trading Update
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an unaudited trading update for the year ended 31 December 2023 ("FY 2023").
The Company expects to report full-year revenues and adjusted EBITDA1 in-line with management expectations, reflecting continued steady growth from the Point-of-Care division and β-HB sales. Cash, net of bank borrowings, as at 31 December 2023, was £4.4m.
Good progress continues to be made in the Life Sciences division's fermentation capacity expansion. Purchase orders for precision fermentation services using the new facility have been received and the Company continues to onboard a number of customers. The Board anticipates that a steady build-up of revenues generated from the new fermentation capacity through 2024, alongside maintained growth across Point-of-Care and β-HB sales.
EKF will announce its FY 2023 results in late March 2024 and provide further insight to expected performance for the current financial year at that time.
1Earnings before interest, tax, depreciation and amortisation, excluding exceptional items and share based payments.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair / Stephen Young, CFO | Tel: +44 (0)29 2071 0570 |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Oliver Platts | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.